1. Home
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
NSCLC: Update Bulletin [April 2016]

NSCLC: Update Bulletin [April 2016]

  • April 2016
  • ID: 3866837
  • Format: PDF
  • Firstword Pharma


Gain new KOL insights on the latest events with the potential to shape the targeted treatment of Non-Small Cell Lung Cancer (NSCLC). Topics covered include opinions about the FDA advisory committee vote against approval of Clovis’s EGFR inhibitor rociletinib, the US FDA priority review granted for Roche’s PD-L1 inhibitor atezolizumab for the treatment of locally advanced or metastatic NSCLC expressing PD-L1, the EMA’s CHMP recommendation for approval of BMS’s Opdivo (nivolumab) for the treatment of locally advanced or metastatic NSCLC after prior chemotherapy, OSE Pharma’s Phase III trial of its OSE 2101 vaccine for the second- or third-line treatment of advanced HLA-A2 positive NSCLC, the US FDA and EU approval Boehringer Ingelheim's afatinib (Gilotrif /Giotrif) for the treatment of advanced squamous NSCLC that has progressed on or after platinum-based chemotherapy, and Ariad’s initiation of Phase III development of its ALK inhibitor brigatinib.

What factors were primarily responsible for the negative FDA review for Clovis’s rociletinib, and what lessons can be learned?
How do KOLs view the likely outcome of the TIGER-3 trial of Clovis’ rociletinib?
Assuming Clovis’ rociletinib finally gains approval, how successful will it be in competing with Tagrisso (osimertinib; AstraZeneca)?
How do KOLs view Roche’s anti- PD-L1 monoclonal antibody, atezolizumab, compared with BMS’ Opdivo (nivolumab) and Merck & Co.’s Keytruda (pembrolizumab)?
How do KOLs rate PD-L1 as a biomarker to guide the treatment of NSCLC with Roche’s atezolizumab?
How do KOLs interpret the recent broadening of Opdivo’s indication in the EU?
How will the widening of the US and EU indication for Giotrif/Gilotrif (afatanib; Boehringer Ingelheim) impact its use?
What expectations do KOLs hold for OSE Pharma’s OSE 2101 as a potential NSCLC treatment?
How do KOLs rate Ariad’s brigatinib as a potential treatment for ALK-positive NSCLC?

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Anti-Tumor Drugs Market Research Report by Indications, Route of Administration, Drug, Drug Class, End User, Distribution Channels, State - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - United States Forecast 2023-2030

  • $ 3949
  • January 2023
  • 147 pages

Anti-Tumor Drugs Market Research Report by Indications (Breast Cancer, Leukemia, and Lung Cancer), Route of Administration, Drug, Drug Class, End User, Distribution Channels, State - Cumulative Impact ...

  • United States
  • In-Store Retail
  • Targeted Therapy
  • Industry analysis


Reportlinker.com © Copyright 2023. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on